NCT03602157View on ClinicalTrials.gov

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

PHASE1RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2041

Conditions
LymphomaImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphoproliferative DisordersNeoplasmsCutaneous LymphomaCutaneous Anaplastic Large Cell LymphomaMycosis FungoidesSezary SyndromeLymphomatoid PapulosisCutaneous T Cell LymphomaGray Zone Lymphoma
Interventions
BIOLOGICAL

ATLCAR.CD30.CCR4 cells

Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8

BIOLOGICAL

ALTCAR.CD30 cells

Fixed dose level of 1x10\^8

DRUG

Bendamustine

70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion

DRUG

Fludarabine

30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT03602157 - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Biotech Hunter | Biotech Hunter